May 14th 2024
Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.
Renal Biopsy Data Supports Long-Term Voclosporin Use for Lupus Nephritis
May 5th 2023Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.
Increased Risk of Fetal and Maternal Morbidity in Systemic Lupus Erythematosus
Compared with those without SLE, those with SLE had a higher risk of fetal morbidity and mothers were almost 4 times as likely to require a blood transfusion or develop a cerebrovascular disorder.
Hoang Nguyen, PhD: Lupus Research Alliance Announces Partnership With FDA, Lupus Community
The collaboration, titled the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), is the first public-private partnership designed to advance lupus discoveries and highlight patient perspective in drug development.
Better Self-Efficacy Linked to Better Health-Related Quality of Life in Patients With SLE
Multivariable models indicated that improvements in the physical component score and mental component score could be predicted by better self-efficacy scores in patients with systemic lupus erythematosus.
Vitamin D Deficiency Common Among Patients with Systemic Lupus Erythematosus
The 2-phase study analyzed the association of plasma vitamin D levels with clinical phenotype, serology, and disease variables in a large cohort of patients with systemic lupus erythematosus living in India.
Risk of Pregnancy Complications Greater in Women with Systemic Lupus Erythematosus
June 18th 2022Data from an analysis of the National Inpatient Sample provides insight into the risk of pregnancy complications among women with systemic lupus erythematosus compared to their counterparts without systemic lupus erythematosus in the US over a decade-long period.
Albert Roy: Clinically Significant Phase 2 Data Evaluates Deucravacitinib for SLE Treatment
Albert Roy, of Lupus Therapeutics, comments on the recent phase 2 trial data that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.
Lupus Nephritis: TULIP-LN Hints at a Blossoming Role for Anifrolumab
May 10th 2022In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.
From Living BLISSfully to BEATing Lupus: Future Considerations for Biologic Therapy in SLE
May 9th 2022After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.